Abstract
The cytochromes P450 are a family of heme-containing proteins with a major role in the oxidation of both xenobiotics (including prescribed drugs) and endogenous compounds. There are at least 57 human P450s (termed isoforms) which are all encoded by separate genes but only 10 of these contribute to drug metabolism, with the major contribution coming from only 3 isoforms, CYP3A4, CYP2D6 and CYP2C9. It is now well recognised that most cytochrome P450 genes are subject to genetic polymorphism and that therefore some individuals have sequence changes present that result in the production of an enzyme with altered catalytic activity or give rise to abnormal gene expression. This article describes the range of genetic polymorphisms now known to occur in the drug metabolizing cytochromes P450 with particular reference to their functional effects and the influence of ethnic origin on the frequency of variant alleles. The relevance of the various polymorphisms to drug response and toxicity is considered as well as the possibility that genotype for these polymorphisms may be a determinant for “personalized prescribing” in the future.
Keywords: Cytochromes P450, endogenous compounds, polymorphisms, CYP3A4, CYP2D6 and CYP2C9
Current Topics in Medicinal Chemistry
Title: Pharmacogenetics of the Cytochromes P450
Volume: 4 Issue: 16
Author(s): Ann K. Daly
Affiliation:
Keywords: Cytochromes P450, endogenous compounds, polymorphisms, CYP3A4, CYP2D6 and CYP2C9
Abstract: The cytochromes P450 are a family of heme-containing proteins with a major role in the oxidation of both xenobiotics (including prescribed drugs) and endogenous compounds. There are at least 57 human P450s (termed isoforms) which are all encoded by separate genes but only 10 of these contribute to drug metabolism, with the major contribution coming from only 3 isoforms, CYP3A4, CYP2D6 and CYP2C9. It is now well recognised that most cytochrome P450 genes are subject to genetic polymorphism and that therefore some individuals have sequence changes present that result in the production of an enzyme with altered catalytic activity or give rise to abnormal gene expression. This article describes the range of genetic polymorphisms now known to occur in the drug metabolizing cytochromes P450 with particular reference to their functional effects and the influence of ethnic origin on the frequency of variant alleles. The relevance of the various polymorphisms to drug response and toxicity is considered as well as the possibility that genotype for these polymorphisms may be a determinant for “personalized prescribing” in the future.
Export Options
About this article
Cite this article as:
Daly K. Ann, Pharmacogenetics of the Cytochromes P450, Current Topics in Medicinal Chemistry 2004; 4 (16) . https://dx.doi.org/10.2174/1568026043387070
DOI https://dx.doi.org/10.2174/1568026043387070 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry The Medical Implications of Gastrointestinal Vagal Afferent Pathways in Nausea and Vomiting
Current Pharmaceutical Design Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Cross-Talk between Tumor Cells and the Microenvironment at the Metastatic Niche
Current Pharmaceutical Biotechnology Cannabinoid Receptor Activation and the Endocannabinoid System in the Gastrointestinal Tract
Current Neuropharmacology Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults
Current Medicinal Chemistry HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Carbonic Anhydrase Based Biomarkers: Potential Application in Human Health and Environmental Sciences
Current Biomarkers (Discontinued) Curcumin: A Promising Agent Targeting Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry